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Abstract
The first contact a virus makes with cells is an important determinant of its tropism. Murid Herpesvirus-4 (MuHV-4) is highly
dependent on glycosaminoglycans (GAGs) for cell binding. Its first contact is therefore likely to involve a GAG-binding virion
glycoprotein. We have previously identified two such proteins, gp70 and gp150. Gp70 binds strongly to GAGs. However,
deleting it makes little difference to MuHV-4 cell binding or GAG-dependence. Deleting gp150, by contrast, frees MuHV-4
from GAG dependence. This implies that GAGs normally displace gp150 to allow GAG-independent cell binding. But the
gp150 GAG interaction is weak, and so would seem unlikely to make an effective first contact. Since neither gp70 nor gp150
matches the expected profile of a first contact glycoprotein, our understanding of MuHV-4 GAG interactions must be
incomplete. Here we relate the seemingly disconnected gp70 and gp150 GAG interactions by showing that the MuHV-4 gH/
gL also binds to GAGs. gH/gL-blocking and gp70-blocking antibodies individually had little effect on cell binding, but
together were strongly inhibitory. Thus, there was redundancy in GAG binding between gp70 and gH/gL. Gp150-deficient
MuHV-4 largely resisted blocks to gp70 and gH/gL binding, consistent with its GAG independence. The failure of wild-type
MuHV-4 to do the same argues that gp150 is normally engaged only down-stream of gp70 or gH/gL. MuHV-4 GAG
dependence is consequently two-fold: gp70 or gH/gL binding provides virions with a vital first foothold, and gp150 is then
engaged to reveal GAG-independent binding.
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Introduction
Many herpesviruses use glycosaminoglycans (GAGs) for their first
cell contact. Murid Herpesvirus-4 (MuHV-4) is highly dependent on
GAGs for cell binding and infection [1]. Its ORF4 encodes a strong
GAG-binding virion glycoprotein, gp70 [2], which is homologous to
the Kaposi’s Sarcoma-associated Herpesvirus ORF4 gene product
[3], and analogous to the Herpes Simplex virus gC [4]: all are
complement control proteins that also bind to GAGs [5]. But if a
need for GAG binding by gp70 explained MuHV-4 GAG-
dependence, then gp70-deficient MuHV-4 should bind poorly to
GAG
+ cells, much as the wild-type binds poorly to GAG
2 cells [6].
Instead, gp70-deficient MuHV-4 shows little deficit in binding or
infection, and is if anything better inhibited by soluble heparin than
thewild-type[2].Also,muchofthegp70onMuHV-4virionsispost-
translationallycleaved toreleaseitsGAG-bindingdomain[2].These
data suggest that gp70 does not provide a particularly important first
contact. It might be more important for saturating the GAGs on
productively infected cells topromote virion release, orfor absorbing
soluble GAGs in infectious foci to stop them inhibiting spread.
Alternatively, its GAG binding might be subservient to complement
evasion [7].
While the contribution gp70 makes to MuHV-4 GAG-
dependence is unclear, there is good evidence for the MuHV-4
gp150 being important [1]. Thus, gp150-specific monoclonal
antibodies (mAbs) increase MuHV-4 infection of GAG-deficient
cells [8] and gp150
2 mutants are almost completely GAG-
independent: they infect GAG
+ cells normally, infect GAG
2 cells
much better than the wild-type does, and largely resist inhibition by
soluble heparin. Interestingly, the gp150 homolog of Epstein-Barr
virus (EBV), gp350, has a similar inhibitory role in making EBV
infection CD21-dependent [9,10]. But unlike the strong CD21
binding of gp350 [11], recombinant gp150 binds to GAGs at best
weakly [2]. This argues against gp150 being important for the initial
capture of virions onto cell surfaces. Also, gp150 knockouts generally
bind better to cells rather than worse. Thus, gp150 is not so much a
cell binding protein as a GAG-sensitive switch, constitutively
inhibiting MuHV-4 infection until GAGs are engaged.
The combination of an abundantly secreted protein that binds
GAGs strongly (gp70) and a regulatory protein that binds GAGs
weakly(gp150)makessenseasavirionreleasemechanism.However,
it leaves unanswered how MuHV-4 virions first attach to cells:
neither gp70 nor gp150 fits the expected profile of a strong cell
binding protein for which the corresponding knockout virus shows a
marked binding deficit. MuHV-4 has at least 2 more cell-binding
virion glycoproteins that could contribute: gB, which binds to cells as
an Fc fusion protein [2]; and gL, since gL-deficient mutants binding
lesswell than thewild-type toadherentcells[6,12].Because gB binds
to a non-GAG ligand [2], while the MuHV-4 first contact is very
likely to involve GAGs, we focussed here on gL.
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by virtue of its association with gH [13]. As with other
herpesviruses [14,15], the presence or absence of gL sets the
MuHV-4 gH conformation [12,13]. Interestingly, glycosyl-phos-
phatidyl-inositol (GPI)-linked gL still folds gH into its native virion
form [13]. gL is therefore likely to lie close to the virion membrane
in the mature gH/gL heterodimer. This, and the small size of gL,
argue that gL does not bind to cells itself, but rather operates
through its effect on gH. In order to understand better how gH/
gL, gp70, gp150 and gB work together, and how gL might
contribute to virion capture, we expressed recombinant gH/gL
and tested it for cell binding. We found that gH/gL, like gp70,
binds to GAGs. gH alone did not, explaining why a gL deficiency
reduces MuHV-4 binding to adherent cells. GAG binding by gH/
gL also explains the redundancy of gp70. In a refined model, we
propose that MuHV-4 first engages cells through either gH/gL or
gp70 binding GAGs. Gp150 displacement then allows GAG-
independent cell binding, probably by gB.
Results
GAG binding by recombinant gH/gL
We first attempted to make a soluble MuHV-4 gH/gL
heterodimer by co-expressing an Fc fusion of the gH extracellular
domain with gL, as done for Herpes simplex virus [16]. This
failed. We have previously observed that although gL is bound to
gH in virions, the transfected MuHV-4 gL folds GPI-linked gH
poorly [13]. gH and gL associate in the endoplasmic reticulum of
infected cells, as pulse-labelled, endoglycosidase H-sensitive gH
displays gH/gL epitopes [13]. But whereas the Herpes simplex
virus gH is retained in the endoplasmic reticulum without gL [14],
the MuHV-4 gH is exported [13]. Other MuHV-4 glycoproteins
may therefore be needed to keep gH and gL together. Notably,
virion gH/gL is normally associated with gB and probably also
with gp150 [6].
In contrast to soluble gL, GPI-linked gL folds gH-GPI quite well
[13]. This applied also to gH with its native transmembrane
domain (Fig. 1A). Some gL immobilization may therefore suffice
to stabilize gH/gL. We have previously made a membrane-bound
form of gH/gL by fusing GPI-linked gL to the gH extracellular
domain [17]. This construct reconstituted the epitopes of 42/42
gH/gL-specific mAbs, all derived from infected mice and specific
for conformational epitopes displayed on infected cells (data not
shown). We reasoned that a gH-gL fusion protein reproduces the
native gH/gL extracellular domain, and so used the same
approach to make soluble gH/gL.
Flow cytometry established that a gH-gL-Fc fusion (gHL-Fc)
reached the plasma membrane of transfected cells and reproduced
native gH/gL epitopes (Fig. 1B). gHL-Fc but not gH-Fc recovered
from transfected cell supernatants bound to BHK-21 cells (Fig. 2A).
Other Fc fusion proteins are shown for comparison. Expression
levels for each are shown in Fig. 2B. Gp70-SCR12-Fc incorpo-
rates the gp70 GAG-binding domain [2]. gB-N-Fc incorporates
the N-terminal MuHV-4 gB furin cleavage product [18],
equivalent to domains I and II of the Herpes simplex virus gB
[19]. Both bound to BHK-21 cells. The N-terminal third of gp150
fused to GST can bind to GAGs at high dose [2], but neither the
same portion of gp150 nor the full-length extracellular domain
(shown here) did so when fused to IgG Fc, presumably because
gp150 binds to GAGs with very low affinity. Neither gp70-
SCR12-Fc nor gHL-Fc bound to GAG-deficient CHO cells, and
both had their binding to GAG
+ CHO cells blocked by pre-
incubation with soluble heparin (Fig. 2C). Both therefore
depended on GAGs for binding.
gH/gL precipitation from virion lysates by heparin-
agarose
We previously failed to identify gH/gL by precipitating virion
proteins with heparin-agarose [2]. Two factors probably contribut-
ed. First, we have no antibody that immunoblots gH, making it
harder to detect than gB, gp150 or gp70. Second, we used Triton X-
100 virion lysates. Fig. 1 suggests that the MuHV-4 gH and gL do
not form a stable heterodimer without other virion proteins. gB may
be one, since it associates with gH/gL and hides parts of it from
antibody [20]. The gH/gL/gB association is preserved in digitonin
but lost in Triton X-100 [6]. Thus, gB dissociation in Triton X-100
may destabilize gH/gL. We have immunoprecipitated gH/gL from
Triton X-100 virion lysates with gH/gL-specific mAbs [12]. But
mAb binding would provide considerable extra stability; heparin-
agarose binding may not. We therefore tested heparin-agarose for
gH/gL precipitation using digitonin virion lysates (Fig. 3).
Figure 1. Expression of gH/gL as a single Fc fusion protein. A.
293T cells were transfected with different expression plasmids. 48h later
they were trypsinized and analyzed by flow cytometry for expression of
gH with mAb 8C1 (short dashes) or gH/gL with mAb 7E5 (long dashes).
Control=secondary antibody only (solid lines). ‘‘gH+gL ORF’’ used the
full-length genomic ORF47; ‘‘gH+gL’’ used the RACE-mapped gL, which
starts at the 5th in-frame ORF47 AUG codon [9]; ‘‘gH+gL-GPI’’ used a
GPI-linked form of the RACE-mapped gL. In each case, gH was
expressed from the full-length genomic ORF22. nil=untransfected. B.
293T cells were transfected with diferent gH expression plasmids or left
untransfected (nil), and 48h later analyzed for gH expression with mAb
8C1 (short dashes, white arrow) and for gH/gL expresion with mAb 7E5
(long dashes, grey arrow), as in A. Solid lines/black arrow=secondary
antibody only. gHL-GPI and gHL-Fc are the same fusion protein with
either a C-terminal GPI anchor or human IgG1-Fc. Each histogram shows
10,000 cells. Both gH-specific and gH/gL-specific staining was
significantly increased after gHL-Fc transfection compared with controls
(p,0.00001 by Student’s t test). Equivalent results were obtained in a
repeat experiment.
doi:10.1371/journal.pone.0001669.g001
MuHV-4 gH/gL
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gH-specific immunoprecipitates, which corresponds to gH [13].
This band was not obvious in heparin-agarose precipitates due to
background bands at the same molecular weight. We therefore
immunoblotted the precipitates with an MuHV-4-immune rabbit
serum, which (among other virion glycoproteins) recognizes gH
[13] (Fig. 3B). This identified an 85 kDa band precipitated by
heparin-agarose from gL
+ but not gL
2 lysates. (The faint
background band in the gL
2 lane has a slightly lower molecular
weight.) The same band was immunoprecipitated from gL
+ and
gL
2 lysates by a gH-specific mAb and only from gL
+ virion lysates
by a gH/gL-specific mAb, confirming that it was gH (Fig. 3B). The
70 kDa band precipitated from gL
+ and gL
2 lysates by heparin-
agarose corresponds to gp70 [2].
The immune serum more strikingly detected the characteristic
bands of virion gB-a minor 120 kDa full length form and its more
abundant 65 kDa N-terminal and 55 kDa C-terminal cleavage
products [18,21]-whenever the 85 kDa band was present. The
presence of gB was confirmed by immunoblotting the same
precipitates with a gB-specific mAb (Fig. 3C). The precipitation of
gB by heparin-agarose was initially puzzling, since we have
previously shown that gB does not bind to GAGs [2]. Specifically,
gB-N-Fc binding to cells is GAG-independent; heparin-agarose does
not precipitate gB from Triton X-100 virion lysates; and the
‘‘heparin-binding’’ motif of gB is buried rather than accessible in its
crystal structure [2,19]-even allowing for gB conformation changes
akinto thoseofthe Vesicular stomatits virus glycoproteinG [22],itis
hard to see how this motif could participate in GAG binding.
However, gB precipitation from digitonin lysates by heparin-agarose
was entirely consistent with gH/gL binding to GAGs, since in
digitoningBremainsattachedtogH/gL[6].ThisisseenbygBbeing
precipitated from gL
+ and gL
2 lysatesbya gH-specific mAb and just
from gL
+ lysates by a gH/gL-specific mAb (Fig. 3B, 3C). The co-
precipitated gB was more obvious than the precipitated gH/gL in
Fig. 3B simply because the MuHV-4-immune rabbit serum, which
recognizes gB [18], immunoblots gB better than it immunoblots gH.
MAb blockade of GAG binding by gHL-Fc
Further support for a physiologically relevant interaction between
gH/gL and GAGs came from antibody blocking (Fig. 4). In Fig. 4A,
mAb LT-6E8 specifically inhibited gp70-Fc binding, mAb 8F10
specifically inhibited gHL-Fc binding and a gB-specific mAb
inhibited neither. The gH/gL-specific mAbs 230-4A2 and 230-
5B2 also completely blocked gHL-Fc binding. Several other gH/gL-
specific mAbs had partial effects, but multiple IgM, IgG2a,I g G 1 and
IgG2b control mAbs failed to block either Fc fusion protein (data not
shown). Thus, the blocking was antigen-specific.
Figure 2. gHL-Fc binds to GAGs. A. Supernatants from 293T cells transfected with expression constructs for different IgG-Fc fusion proteins were
used to stain BHK-21 cells. gp70-SCR12=short consensus repeats 1 and 2 of gp70, which include its heparin-binding site; gB-N=gB N-terminal to its
furin cleavage site, which incorporates its cell-binding domain. To retain GAG expression, the cells were plated onto Petri dishes 18h before staining
and then detached without trypsinization. Control=untransfected 293T cell supernatant plus secondary antibody. Equivalent data were obtained in 4
repeat experiments. B. The transfected cell supernatants from A were immunoblotted for their common human IgG-Fc domain. nil=untransfected
cell supernatant. gp70=Fc fusion of the full-length protein, which was not used here. C. GAG
+ CHO cells or the GAG-deficient CHO-745 mutant
(GAG
2) were stained with Fc fusion proteins as indicated, either in the presence (dashed lines) or absence (solid lines) of 300 mg/ml heparin.
nil=secondary antibody only. Equivalent data were obtained in 2 repeat experiments.
doi:10.1371/journal.pone.0001669.g002
MuHV-4 gH/gL
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on MuHV-4-infected cells. Thus, their capacity to block GAG
binding by gHL-Fc argued that this involves native gH/gL epitopes.
The capacity of gH/gL-specific mAbs to block gHL-Fc binding did
not particularly correlate with virion neutralization (Fig. 4B). For
example,mAbs7E5andT2C12,whichdefinethetwomajorgH/gL
neutralization epitopes [13], both failed to inhibit gHL-Fc binding.
And while the gHL-Fc blocking mAbs 8F10, 230-4A2 and 230-5B2
all have neutralizing activity, it was less than that of 7E5 or T2C12
(data not shown). Indeed, gHL-Fc blocking does not necessarily
explain the neutralization by 8F10, 230-4A2 or 230-5B2; an
inhibition of membrane fusion is also possible. MAb 230-5H6
defines a gH/gL epitope that is normally protected by the gB N-
terminus, but is a neutralization target when the gB N-terminus is
deleted [20]. It failed to block gHL-Fc binding. Nor did gH-specific
mAbs block binding-MG-4A12 provides a representative example-
consistent with gH-Fc failing to bind GAGs (Fig. 1B).
MAb blockade of cell binding by MuHV-4 virions
The weak GAG binding of gp150 [2] seemed unlikely to
compensate directly for a lack of gH/gL or gp70. But gp70 and
Figure 3. Virion gH/gL binds to GAGs. A. Wild-type (gL
+)a n dg L -
deficient (gL
2) virions were lysed in 1% digitonin, then immunoprecip-
itated with either heparin-agarose or protein A-sepharose plus mAb 7E5
(gH/gL-specific) or 8C1 (which recognizes all forms of gH). The washed
precpitates were denatured, resolved by SDS-PAGE and visualized by
Coomassie staining. The positions of gH (85 kDa) and IgG heavy chains
(Ig-H,50–55 kDa)areshown.ThegHsignalwas weak but clearlyvisibleby
comparison with the gL
2 virion/gH/gL IP control. The data are from 1 of 2
equivalent experiments. B. The same precipitates as in A were
immunoblotted with a MuHV-4-immune rabbit serum, which recognizes
(among other virion proteins) gp70,gp150, gB and gH.The MuHV-4virion
glycoproteins are readily distinguished by SDS-PAGE. The positions of gH
(85 kDa), gp70, full-length gB (gB-FL, 120 kDa) and the N- and C-terminal
gB cleavage products (gB-N, 65 kDa; gB-C, 55 kDa) are shown. The data
are from 1 of 2 equivalent experiments. C. The same precipitates were
immunoblotted with mAb MG-10C11, which recognizes an epitope in gB-
N. The gB-FL bands are faint because most virion gB is cleaved [18]. The
identity of the 50 kDa band in the heparin IP lanes is unclear. The only
glycoprotein target of MG-10C11 is gB, but it is known to also recognize a
50 kDa virion protein on immunoblots [21].
doi:10.1371/journal.pone.0001669.g003
Figure 4. Inhibtion of Fc fusion protein binding by mAbs. A.
Gp70-SCR12-Fc (dashed lines)=SCR domains 1+2 of gp70. gHL-Fc (solid
lines) =gH fused to C-terminal gL. Each Fc fusion protein was
preincubated or not with mAbs as indicated and then used to stain
BHK-21 cells. The filled histogram (nil) shows secondary antibody only
staining. Similar data were obtained in 2 repeat experiments. B. Further
gH-specific mAbs (see main text) were tested for their capacity to block
gHL-Fc binding to BHK-21 cells.
doi:10.1371/journal.pone.0001669.g004
MuHV-4 gH/gL
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antibodies specific for one or the other from blocking virion
binding. This would explain why gp70 is a poor neutralization
target and why gH/gL-specific neutralizing mAbs act mainly after
binding [13]. Consistent with such an idea, synergistic neutrali-
zation was observed between mAbs LT-6E8 and 230-4A2
(Fig. 5A). LT-6E8 alone had little effect except at very high dose;
230-4A2 alone gave some neutralization, possibly by inhibiting
infection post-binding; but LT-6E8 and 230-4A2 together were
strongly neutralizing. We observed a similar synergistic blockade
of virion binding (Fig. 5B, 5C): either mAb alone had much less
effect than both combined.
The capacity of gp70 and gH/gL each to compensate for a loss of
GAG binding by the other was confirmed with knockout viruses
(Fig. 5D). gL-deficient MuHV-4 was much more potently
neutralized than the wild-type by mAb LT-6E8; and gp70-deficient
MuHV-4 was more potently neutralized than the wild-type by the
gH/gL blocking mAbs 230-4A2 and 230-5B2. Thus, virions showed
redundancy in GAG binding between gp70 and gH/gL.
Neutralization directed against GAG binding in the
absence of gp150
Gp150 is a major determinant of MuHV-4 GAG dependence,
since gp150
2 viruses are much less GAG-dependent than the wild-
type [1]. The main deficit of gp150 knockouts is poor virion
release, presumably because their GAG-independent virions are
recaptured onto the GAG-deficient surfaces of infected cells [1].
This phenotype implies that gp150 normally covers a cell-binding
epitope. The protected epitope is unlikely to be on gH/gL or gp70,
since it binds a non-GAG ligand. Also, gL
2gp150
2 [6] and
gp70
2gp150
2 mutants (data not shown) both retain the increased
binding to GAG-deficient cells of the gp150
2 mutant.
We tested whether the gp150-regulated binding could compen-
sate for a lack of gH/gL or gp70 binding by comparing the
antibody-mediated blockade of gp150
+ and gp150
2 virions
binding to GAG
+ and GAG
2 CHO cells (Fig. 6). For CHO
GAG
+ cells, antibody had less effect on either binding or infection
when gp150 was lacking (compare the wild-type and knockout
viruses). As expected, antibody was poorly effective against either
virus infecting GAG
2 CHO cells (where wild-type infectivity is
anyway low). The modest reduction in infectivity with mAb 230-
4A2 presumably reflected a post-binding block of membrane
fusion. The complexity of virus/cell interactions must be borne in
mind when interpreting these data: GAG
+ and GAG
2 CHO cells
may differ in more than GAG expression; high virion avidity may
allow gp70 and gH/gL to bind other polyanions in some settings;
and gp150 deficiency may have knock-on effects on other virion
glycoproteins. But the results argued strongly that gp70 and gH/
gL between them provide the initial MuHV-4 cell attachment, and
showed that GAG-independent binding can supplant gp70 and
gH/gL only when gp150 is missing. GAG engagement by gH/gL
and gp70 must therefore normally precede gp150 displacement.
Heparin inhibition of MuHV-4 infection
The dual role of GAGs in MuHV-4 entry-binding to gH/gL
and gp70, and relieving the gp150 inhibition of GAG-independent
binding-raised the question as to how soluble heparin inhibits
infection. Heparin blocks wild-type MuHV-4 infection much
better than that of a gp150 knockout [1]. But was the difference
due to non-GAG binding rescuing gp150 knockouts, or to heparin
blocking gp150 displacement rather than gH/gL/gp70 binding?
To address this, we compared GAG
+ and GAG
2 CHO cell
binding and infection by gp150
+ and gp150
2 MuHV-4 at different
heparin concentrations (Fig. 7).
As before, each virus infected GAG
+ CHO cells to much the
same level, and the gp150 knockout infected GAG
2 CHO cells
much better than wild-type MuHV-4 did. Heparin also blocked
wild-type MuHV-4 much better than the gp150 knockout for
GAG
+ CHO cell infection and binding, consistent with the
antibody blockade differences in Fig. 6. As expected, heparin had
little effect on either virus binding to or infecting GAG
2 CHO
cells. The key finding was that the binding and infection blocks for
wild-type MuHV-4 on GAG
+ CHO cells titrated out similarly.
Thus, there was no evidence for heparin blocking a post-binding
gp150 displacement better than the initial gp70/gH/gL cell
binding. The data argued instead for a simple, heparin-mediated
binding block from which gp150
2 MuHV-4 could be rescued by
GAG-independent binding. The non-availability of this ligand to
gp150
+ MuHV-4 fitted with GAG-dependent cell binding
preceding gp150 displacement.
Discussion
MuHV-4 infection is highly GAG-dependent. We previously
identified gp150 as a key mediator of this dependence, in that
disrupting gp150 makes infection GAG-independent [1,2]. The
present data refine this model by showing that MuHV-4 has 2
GAG-binding proteins-gp70 and gH/gL-which act upstream of
gp150. Gp70 and gH/gL between them provide MuHV-4 with its
vital first cell contact. MuHV-4 GAG dependence is consequently
twofold: first gH/gL or gp70 must attach virions to cellular GAGs;
then GAGs interact with gp150 to allow GAG-independent
binding. We presume that gp150 displacement reveals an epitope
on gB, since this is the only MuHV-4 glycoprotein known to have
a non-GAG ligand. Direct evidence for a gB/gp150 interaction is
lacking, but however gB is engaged, the different MuHV-4 GAG
interactions are now seen to make a functionally coherent whole,
combining efficient virion capture with down-stream binding
initiated only at the cell surface.
Why does MuHV-4 have multiple GAG-binding proteins? The
gp150/GAG interaction can be explained as triggering rather than
adhesion, but this still leaves redundancy between gp70 and gH/gL.
gL could have a particular role in gp150 displacement, since a gL
deficiency somewhat reduces the virion gp150 content [6]. But gL
2
virions show no qualitative difference in gp150 function, only a mild
deficiency phenotype commensurate with their reduced gp150
content[6].(Gp70knockoutsshownogp150deficiency[2].)Itseems
more likely that gH/gL GAG binding allows for the effects of gp70
cleavage. Immunoblots indicate that BHK-21 cell-derived virions
shed the GAG binding domain from at least 50% of their gp70 [2].
This may be important for efficient virion release, or for other gp70
functions such as complement evasion [7]. It may also be cell type-
dependent [2]. If little gp70 were left uncleaved, GAG binding by
gH/gL would be vital for attachment.
MuHV-4 is similar in its GAG-dependence not only to other
herpesviruses [23] but also to unrelated viruses [24] and other,
more complex intracellular pathogens [25]. GAGs evidently
provide a useful general way to attach to and infect host cells.
The ubiquity of GAG expression must confer on GAG-binding
virions a general stickiness that helps to keep them cell-associated.
Both virions and GAGs are inherently repetitive, so high avidity
will tend to make their interaction irreversible. This emphasizes
the general problem faced by virions passing between hosts, that
they must combine efficient release from one epithelial surface
with efficient penetration of the next. The predominant localiza-
tion of GAGs to basolateral rather than apical epithelial surfaces
[26] would allow MuHV-4 reactivating from a latently infected B
cell to engage GAGs and infect epithelial cells basolaterally, before
MuHV-4 gH/gL
PLoS ONE | www.plosone.org 5 February 2008 | Volume 3 | Issue 2 | e1669Figure 5. Inhibition of MuHV-4 infection by gp70-Fc and gHL-Fc blocking mAbs. A. Wild-type virions (200 p.f.u.) were incubated with
mAbs as shown (2h, 37uC) then plaque-assayed on BHK-21 cells. We compared pairs of treatment arms by scoring (+ or -) for each antibody dilution
whether the titer of a given treatment arm was more or less than the mean of both. We then performed an exact Chi-squared test on the
comparisons. By this measure, mAb 230-4A2 but not mAb LT-6E8 gave significant neutralization, and 230-4A2 plus LT-6E8 was significantly better
than 230-4A2 alone (p,0.0001). Equivalent data were obtained in 2 further experiments. B. Wild-type virions were incubated with mAbs (2 h, 37uC,
1 mg/1000 p.f.u.) then bound to either BHK-21 or NMuMG cells (2 h, 37uC, 3 p.f.u./cell). Bound virions were detected by washing, fixing and
permeabilizing the cells, then staining them for gN with mAb 3F7. Secondary detection was with Alexa488-conjugated goat anti-mouse IgG pAb. This
would have detected mAbs LT-6E8 and 230-4A2 even if the gN epitope were masked. The cells were scored simply as positive or negative on
staining. Each bar shows the % positive of 10,000 cells, based on a gate where unexposed cells were 0% positive. The differences in binding between
no mAb block/single mAb block, and between single mAb block/dual mAb block were highly significant (p,0.0001 by Student’s t test). Equivalent
data were obtained in 1 further experiment. C. Wild-type, gp70-deficient or gL-deficient virions (200 p.f.u.) were each incubated with mAbs (2h, 37uC,
1 mg/1000 p.f.u.), then with BHK-21 cells (2h, 37uC, 3 p.f.u./cell) as in B. The cells were then washed x3 in PBS, fixed and permeabilized, stained for gN
with mAb 3F7 (green), counterstained with DAPI (blue) and examined microscopically for virion uptake. As in B, the anti-mouse secondary antibody
would also have detected bound 230-4A2 or LT-6E8, so we could be sure no virions were missed because mAb binding had masked gN. D. Wild-type,
gp70-deficient or gL-deficient virions (200 p.f.u.) were each incubated with mAbs as shown (2h, 37uC) then plaque assayed on BHK-21 cells. 230-4A2
and 230-5B2 both block gHL-Fc binding; LT-6E8 blocks gp70-Fc binding. Titers are plotted as % of p.f.u. without mAb for each virus. We compared
treatment arms by an exact Chi-squared test of the pairwise comparisons at each antibody dilution, as in A. By this measure, mAb LT-6E8 neutralized
the gL knockout but not the wild-type or gp70 knockout, and mAbs 230-4A2 and 230-5B2 neutralized the wild-type and gp70 knockout-the gp70
knockout significantly better than the wild-type-but not the gL knockout (p,0.004). The data are from 1 of 5 equivalent experiments.
doi:10.1371/journal.pone.0001669.g005
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on infected cells [1] and shedding of the gp70 GAG binding
domain [2] would compensate for any local breakdown of the
epithelial barrier. The GAG shedding that accompanies inflam-
mation [27] could also help. But the GAG-dependent virions
would then have to reach basolateral GAGs to infect new hosts.
Mucosal sampling pathways such as M cell transcytosis [28] may
therefore be important for primary MuHV-4 infection: moving
virions from the apical to the basolateral epithelial surface and
initiating infection from underneath. Understanding herpesvirus
transmission and how to prevent it clearly require that we learn
more about virion uptake. The two-fold GAG-dependence of
MuHV-4 implies that its incoming virions somehow reach the
basolateral epithelial surface.
Materials and Methods
Viruses
All viruses were derived from a cloned MuHV-4 BAC [29].
Unless indicated, the loxP-flanked BAC cassette, which includes a
human cytomegalovirus IE1 promoter-driven eGFP expression
cassette, was removed by virus passage through NIH-3T3-CRE cells
[30]. Gp70-deficient [29], gL-deficient [12] and gp150-deficient [1]
MuHV-4 BAC mutants have been described, as have derivatives
with eGFP-tagged glycoprotein M, which make fluorescent virions
[21]. Virus stocks were grown and titered by plaque assay in BHK-
21 cells [1]. Infected cells and supernatants were sonicated after
harvesting, cell debris was pelleted by low-speed centrifugation
(10006g, 3 min), and virions were recovered from supernatants by
high speed centrifugation (380006g,9 0m i n ) .
Cells
BHK-21 cells, NMuMG epithelial cells (American Type
Culture Collection CRL-1636), CHO-K1 cells, the GAG-deficient
CHO-745 mutant, NIH-3T3-CRE cells and 293T cells were all
grown in Dulbecco’s modified Eagle medium (Invitrogen, Paisley,
U.K.) supplemented with 2 mM glutamine, 100 U/ml penicillin,
100 mg/ml streptomycin and 10% fetal calf serum (PAA
laboratories, Linz, Austria). Cells were transfected using Fugene-
6 (Roche Diagnostics Ltd., Lewes, U.K.).
Plasmids
A human IgG1-Fc fusions of gp70 short consensus repeats 1+2
has been described [2], as has an equivalent fusion of the N-
terminal half of gB [2]. The coding sequence for amino acid
residues 1–450 of gp150 was PCR-amplified (Phusion DNA
polymerase, New England Biolabs, Hitchin, U.K.) with 59 XbaI-
Figure 6. Gp150 deficiency alleviates an antibody-mediated block to GAG binding. A. EGFP-expressing wild-type or gp150 knockout
virions were incubated with mAbs as shown, then used to infect GAG
+ and GAG
2 CHO cells. Infection was assayed 18h later by flow cytometry of viral
eGFP expression, counting the %eGFP
+ cells in a gate where uninfected cells (no virus) were ,0.2% eGFP
+. A log scale is used to encompass the large
differences in infection between gp150
+ and gp150
2 viruses and between GAG
+ and GAG
2 CHO cells. Each point represents 10,000 cells. Equivalent
data were obtained in a repeat experiment. B. gM-eGFP
+ versions of the same viruses, which have eGFP
+ virions, were incubated with GAG
+ and
GAG
2 CHO cells (2h, 37uC) to allow binding/endocytosis. The cells were then washed x3 in PBS and assayed for eGFP uptake by flow cytometry. Each
point represents 3,000 cells. Equivalent data were obtained in a repeat experiment. We compared viruses and cell types by taking the reduction in
infectivity for each point of each of the 2 experiments (total n=6). We then compared the reductions using Student’s t test. This showed that mAb
230-4A2 and the double antibody treatment both neutralized wild-type MuHV-4 significantly better than the gp150 knockout, and that neutralization
of the wild-type was significantly better with GAG
+ CHO cells than with GAG
2 (p,0.01).
doi:10.1371/journal.pone.0001669.g006
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NotI sites upstream of a human IgG1-Fc coding sequence as for
gp70 and gB [2]. The gH extracellular domain was similarly fused
to IgG1-Fc by PCR amplification of its extracellular domain (amino
acid residues 1–703) with 59 AvrII-restricted and 39 NotI-restricted
primers. gL missing most of its signal sequence was amplified with 59
and 39 NotI-restricted primers, and cloned in-frame into the NotIs i t e
between the gH extracellular domain and IgG1-Fc, as with a GPI-
linked version of the same fusion [17]. The full-length gH
extracellular domain was PCR-amplified with EcoRI and XhoI-
restricted primers and cloned into the EcoRI/XhoI sites of pcDNA3
(Invitrogen Corporation). Expression plasmids for RACE-mapped
gL, the gL ORF and gL-GPI have been described [13]. Fc fusion
proteins were produced by transfecting the expression plasmids into
293T cells using. Supernatants were collected after 48h.
Monoclonal antibodies
All mAbs described were generated from MuHV-4 carrier mice
at least 6 months post-infection and selected for recognition of
MuHV-4-infected BHK-21 cells without permeabilization. Thus,
they define native epitopes on the virion or virus-infected cell
surface. These mAbs were: 7E5, T2C12 [13], 230-5H6, 230-4A2,
8F10 (all anti-gH/gL), 8C1 (recognizes both gH and gH/gL) [13],
MG-4A12 (recognizes gH rather than gH/gL) [12], LT-6E8 (anti-
gp70), MG-4D11 (anti-gB), MG-10C11 (anti-gB) [21], and 3F7
(anti-gN) [31]. MAb 230-5H6 is IgG1; MG-10C11 is IgM; 8C1 is
IgG2b; all the others are IgG2a.
Immunoprecipitation and Immunoblotting
Virions were lysed on ice for 45 min in 1% digitonin, 50 mM
TrisCl pH 7.4, 150 mM NaCl, 5 mM MgCl2 with Complete
protease inhibitors (Roche Diagnostics). Insoluble debris was
pelleted by centrifugation (130006g, 15 min). The lysates were
then incubated with either heparin-agarose beads (Sigma Chem-
ical Co., Poole, U.K.) or mAbs plus protein A-sepharose. The
beads were washed 65 in 0.1% digitonin and heated (95uC,
5 min) in Laemmli’s buffer. The released proteins were then
resolved by SDS-PAGE. For total protein detection, gels were
fixed in 10% acetic acid/50% methanol and stained with
Coomassie R250. For immunoblotting, the proteins were
Figure 7. Comparison of MuHV-4 cell binding and infection in the presence of heparin. A. EGFP-expressing wild-type or gp150
2 virions
were incubated with different heparin concentrations, then used to infect GAG
+ and GAG
2 CHO cells. Infection was assayed 18h later by flow
cytometry of viral eGFP expression, counting the %eGFP
+ cells in a gate where uninfected cells (no virus) were ,0.2% eGFP
+. Each point represents
10,000 cells. The bars show infection levels without heparin. nil=no virus. Equivalent data were obtained in a repeat experiment. B. gM-eGFP
+
versions of the same viruses were incubated with GAG
+ and GAG
2 CHO cells, with or without added heparin (2h, 37uC), then washed x3 in PBS and
assayed for eGFP uptake by flow cytometry. Again, the bars show eGFP uptake without heparin, and nil=no virus. Equivalent data were obtained in a
repeat experiment. The minor increases in gp150
2 binding to and infection of GAG
2 CHO cells at low heparin dose were quite variable between
experiments; the reductions, particularly in wild-type MuHV-4 infection of and binding to GAG
+ CHO cells, were not.
doi:10.1371/journal.pone.0001669.g007
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U.K.). The membranes were blocked with 10% non-fat milk in
PBS/0.1% Tween-20, then incubated with the gB-specific mAb
MG-10C11 or with an MHV-68-immune rabbit serum [32].
Bound antibody was detected with horseradish peroxidase-
conjugated rabbit anti-mouse IgG pAb (Dako Cytomation, Ely,
U.K.) or horseradish peroxidase-conjugated donkey anti-rabbit
IgG pAb (APBiotech, Little Chalfont, U.K.), followed by washing
in PBS/0.1% Tween-20, development with ECL substrate
(APBiotech) and exposure to X-ray film.
Flow cytometry
Cells exposed to HCMV IE1 eGFP
+ or gM-eGFP
+ MuHV-4
were trypsinized and analyzed directly for green fluorescence. For
protein binding, cells were incubated with human IgG-Fc fusion
proteins or with MuHV-4 glycoprotein-specific mAbs (1h, 4uC),
washed 62 in PBS, and then incubated with fluorescein-
conjugated rabbit anti-mouse IgG pAb (Dako Cytomation) or
phycoerythrin-conjugated goat anti-human IgG-Fc pAb (Sigma
Chemical Co.). For total rather than cell surface glycoprotein
detection, the cells were fixed in 2% paraformaldehyde (30 min,
23uC) and permeabilized with 0.1% saponin before staining. All
cells were washed 62 in PBS before analysis on a FACS Calibur
(BD Biosciences, Oxford, U.K.)
Immunofluorescence
BHK-21 cells exposed to MuHV-4, washed with PBS to remove
unbound virions, fixed in 4% paraformaldehyde (room temper-
ature, 30 min), permeabilized with 0.1% Triton X-100, stained for
gN with mAb 3F7 plus Alexa 488-conjugated goat anti-mouse IgG
pAb, washed62, counterstained with DAPI and visualised with an
Olympus microscope plus Retiga 4000R camera line (Qimaging,
Burnaby, Canada).
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